ACUTE MONOBLASTIC LEUKEMIA - CLINICAL AND BIOLOGIC STUDY OF 74 CASES
- 1 January 1980
- journal article
- research article
- Vol. 55 (1) , 71-76
Abstract
Cases (74) of pure acute monoblastic leukemia (AMol) were retrospectively studied. All patients were treated at Hospital Saint-Louis [Paris, France] between 1970-1978. Diagnosis was based on morphological and cytochemical features according to the FAB classification. This type of leukemia occurred at any age and in both sexes, with a high frequency of extramedullary involvements. Hyperleukocytosis was very frequent and was significantly correlated with increased blood and urine levels of lysozyme, with renal failure and hypokalemia and coagulation abnormalities. AMol still has a poor prognosis despite a best remission rate (75%) obtained with rubidazone, since the duration of complete remission was short. Central nervous irradiation prolonged remission and prevented meningeal relapses, while 6 meningeal relapses occurred in patients not irradiated. The high frequency of extramedullary relapses, including gum and skin, emphasized the question of persistant blast cell sanctuaries after achievement of bone marrow remissions. More intensive induction with several drugs active against monoblasts could be more efficient and prolong the duration of complete remissions.This publication has 7 references indexed in Scilit:
- The distinctive features of acute monocytic leukemiaAmerican Journal of Hematology, 1978
- Pure Acute Monocytic Leukemia: A Study of 12 CasesAmerican Journal of Clinical Pathology, 1977
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and designBritish Journal of Cancer, 1976
- Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative GroupBritish Journal of Haematology, 1976
- Clinical study of rubidazone (22 050 R.P.), a new daunorubicin-derived compound, in 170 patients with acute leukemias and other malignanciesCancer, 1976
- SERUM AND URINARY LYSOZYME (MURAMIDASE) IN MONOCYTIC AND MONOMYELOCYTIC LEUKEMIAThe Journal of Experimental Medicine, 1966